| Literature DB >> 25200733 |
Dominic Wilkinson1, Lachlan de Crespigny2, Vicki Xafis3.
Abstract
In clinical practice, and in the medical literature, severe congenital malformations such as trisomy 18, anencephaly, and renal agenesis are frequently referred to as 'lethal' or as 'incompatible with life'. However, there is no agreement about a definition of lethal malformations, nor which conditions should be included in this category. Review of outcomes for malformations commonly designated 'lethal' reveals that prolonged survival is possible, even if rare. This article analyses the concept of lethal malformations and compares it to the problematic concept of 'futility'. We recommend avoiding the term 'lethal' and suggest that counseling should focus on salient prognostic features instead. For conditions with a high chance of early death or profound impairment in survivors despite treatment, perinatal and neonatal palliative care would be ethical. However, active obstetric and neonatal management, if desired, may also sometimes be appropriate.Entities:
Keywords: Ethics; Fatal outcome; Fetal termination; Infant; Medical futility; Newborn; Trisomy
Mesh:
Year: 2014 PMID: 25200733 PMCID: PMC4339700 DOI: 10.1016/j.siny.2014.08.007
Source DB: PubMed Journal: Semin Fetal Neonatal Med ISSN: 1744-165X Impact factor: 3.926
Published outcome for severe congenital anomalies often described as lethal.a
| Severe congenital anomalies | Prevalence | Probability of live birth (in absence of termination) | Median postnatal survival | Proportion surviving >1 week/>1 year | Longest reported survivals |
|---|---|---|---|---|---|
| Renal agenesis | 1.7/10,000 | Not reported | <24 h | <5% | 13 months |
| Anencephaly | 10/10,000 pregnancies | 62–72% | <24 h | 0–14%>1 week/7% >1 year | 10 months |
| Thanatophoric dysplasia | 0.4/10,000 | Not reported | Not reported | Not reported | 5 years |
| Trisomy 18 | 2.6/10,000 | 48–51% | 14 days | 35–65%>1 week/14–19% >1 year | 27 years |
| Trisomy 13 | 1.2/10,000 | 28–46% | 10 days | 45–57%>1 week/14–21% >1 year | 19 year |
| Holoprosencephaly | 0.5/10,000 | Not reported | 4–5 months | 71%>1 week/ 47% >1 year | 6 years |
Using recent population cohort studies where available.